Literature DB >> 26069334

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.

Erik Berntorp1, Alfonso Iorio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26069334      PMCID： PMC4471774          DOI： 10.1182/blood-2014-10-608471

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.

Authors:  J G van der Bom; S C Gouw; F R Rosendaal
Journal:  Haemophilia       Date:  2013-12-26       Impact factor: 4.287

2.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

3.  The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.

Authors:  C M Kessler; A Iorio
Journal:  Haemophilia       Date:  2013-04-12       Impact factor: 4.287

4.  Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Authors:  Thierry Calvez; Hervé Chambost; Ségolène Claeyssens-Donadel; Roseline d'Oiron; Véronique Goulet; Benoît Guillet; Virginie Héritier; Vanessa Milien; Chantal Rothschild; Valérie Roussel-Robert; Christine Vinciguerra; Jenny Goudemand
Journal:  Blood       Date:  2014-09-24       Impact factor: 22.113

5.  Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.

Authors:  Wolfhart Kreuz; Joan C Gill; Chantal Rothschild; Marilyn J Manco-Johnson; Jeanne M Lusher; Elke Kellermann; Eduard Gorina; Peter J Larson
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249
  5 in total
  1 in total

1.  Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Authors:  Thierry Calvez; Hervé Chambost; Roseline d'Oiron; Vincent Dalibard; Virginie Demiguel; Alexandra Doncarli; Yves Gruel; Yoann Huguenin; Patrice Lutz; Chantal Rothschild; Christine Vinciguerra; Jenny Goudemand
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.